3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

Key Takeaways J&J's oncology sales rose 20.6% to $18.52B, fueled by Darzalex, Erleada and new cancer drugs.ImmunityBio's Anktiva gained U.S. approval for NMIBC, with $74.7M in 2025 sales.Foghorn Therapeutics is advancing FHD-909 for SMARCA4-mutant cancers.An updated edition of the October 28, 2025, article.The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement. The American Cancer Society estimates that the United State ...